Sasaki Sanae, Jaimes Maria C, Holmes Tyson H, Dekker Cornelia L, Mahmood Kutubuddin, Kemble George W, Arvin Ann M, Greenberg Harry B
Department of Medicine, Stanford University School of Medicine, CA, USA.
J Virol. 2007 Jan;81(1):215-28. doi: 10.1128/JVI.01957-06. Epub 2006 Oct 18.
Cellular immune responses to influenza virus infection and influenza virus vaccination have not been rigorously characterized. We quantified the effector and memory B-cell responses in children and adults after administration of either live attenuated (LAIV) or inactivated (TIV) influenza virus vaccines and compared these to antibody responses. Peripheral blood mononuclear cells were collected at days 0, 7 to 12, and 27 to 42 after immunization of younger children (6 months to 4 years old), older children (5 to 9 years old), and adults. Influenza virus-specific effector immunoglobulin A (IgA) and IgG circulating antibody-secreting cells (ASC) and stimulated memory B cells were detected using an enzyme-linked immunospot assay. Circulating influenza virus-specific IgG and IgA ASC were detected 7 to 12 days after TIV and after LAIV immunization. Seventy-nine percent or more of adults and older children had demonstrable IgG ASC responses, while IgA ASC responses were detected in 29 to 53% of the subjects. The IgG ASC response rate to LAIV immunization in adults was significantly higher than the response rate measured by standard serum antibody assays (26.3% and 15.8% by neutralization and hemagglutination inhibition assays, respectively). IgG ASC and serum antibody responses were relatively low in the younger children compared to older children and adults. TIV, but not LAIV, significantly increased the percentage of circulating influenza virus-specific memory B cells detected at 27 to 42 days after immunization in children and adults. In conclusion, although both influenza vaccines are effective, we found significant differences in the B-cell and antibody responses elicited after LAIV or TIV immunization in adults and older children and between young children and older age groups.
针对流感病毒感染和流感病毒疫苗接种的细胞免疫反应尚未得到严格的表征。我们对儿童和成人接种减毒活流感疫苗(LAIV)或灭活流感疫苗(TIV)后的效应B细胞和记忆B细胞反应进行了定量,并将这些反应与抗体反应进行了比较。在年幼儿童(6个月至4岁)、年长儿童(5至9岁)和成人接种疫苗后的第0天、第7至12天以及第27至42天收集外周血单个核细胞。使用酶联免疫斑点试验检测流感病毒特异性效应免疫球蛋白A(IgA)和IgG循环抗体分泌细胞(ASC)以及刺激的记忆B细胞。在接种TIV和LAIV疫苗后7至12天检测到循环流感病毒特异性IgG和IgA ASC。79%或更多的成人和年长儿童有可检测到的IgG ASC反应,而29%至53%的受试者检测到IgA ASC反应。成人接种LAIV后的IgG ASC反应率显著高于标准血清抗体检测所测得的反应率(中和试验和血凝抑制试验分别为26.3%和15.8%)。与年长儿童和成人相比,年幼儿童的IgG ASC和血清抗体反应相对较低。TIV而非LAIV显著增加了在接种疫苗后27至42天检测到的儿童和成人循环流感病毒特异性记忆B细胞的百分比。总之,尽管两种流感疫苗都有效,但我们发现成人和年长儿童接种LAIV或TIV后以及年幼儿童和年长儿童组之间在B细胞和抗体反应方面存在显著差异。